St Jude's bipolar lead for CRT (cardiac resynchronisation therapy) devices:
This article was originally published in Clinica
Executive Summary
The US FDA has given St Jude Medical the all-clear to sell its QuickSite 1056T bipolar lead, a product designed for use with the company's Epic and Atlas cardiac resynchronisation therapy (CRT) devices for treating heart failure. "The bipolar lead leverages the clinically proven design of the QuickSite unipolar lead, adding the flexibility of bipolar pacing to better manage patients with phrenic nerve stimulation," said Michael Coyle, president of the St Paul, Minnesota firm's cardiac rhythm management division. The product is scheduled for launch in May 2005.
You may also be interested in...
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.